CPHI North America a ‘one stop shop’ for professional and business development

CPHI events are renowned for connecting pharma players from across the supply chain to learn, grow, and conduct business all over the world.

Attendees can look forward to a packed agenda of learning labs, panel discussions and presentations, where industry trends are discussed by some of the most prominent voices in pharma. Networking opportunities are baked into the event’s structure, encouraging participants to form connections with stakeholders throughout the supply chain.  

According to Wayne Weiner, president of the strategy consultancy Pharmatech Solutions LLC, this access to industry professionals and business development opportunities makes CPHI the ideal ‘one stop shop’ for pharma professionals. Weiner will act as a moderator during two panel discussions this year, one on continuous manufacturing and one on supply chains.  

He tells us why he is returning to Philadelphia, previews his panel topics and reveals what he is most looking forward to this year.  

Register for CPHI North America here.  

Firstly, what are you looking forward to most at CPHI NA this year?  

CPHI NA serves as a significant mid-year opportunity to network with colleagues across the industry, learn about significant trends impacting our industry, and in general develop new business opportunities.   

What should our attendees expect when attending CPHI?  

The opportunity to establish connections with a broad range of industry experts and suppliers, and refresh one’s understanding of the industry.  

We have a packed programme with innovative content throughout the 3 on-site days. Is there a particular session you are excited about? If so, why should people attend?  

Apart from the sessions I am directly involved with, I am most interested to hear about macro trends that impact the pharma industry (such as drug pricing), and topics relating to M&A.  

You will be moderating a panel about rethinking the supply chain at CPHI NA. What do you think are some of the barriers to pharmaceutical manufacturing in the US?  

One should keep in mind that there is a significant level of pharmaceutical manufacturing in the US, and this will remain the case.  The key issue is how this should be ‘adjusted’ going forward to balance the risk (real or perceived) in the global supply chain vs economic considerations (pricing, investment, etc.)   

You will also be moderating a panel on drug manufacturing dynamics at CPHI NA. What do you think is driving the adoption of continuous manufacturing?   

Efficiencies in time to market, economic benefits in scale-up and manufacturing, and environmental/sustainability benefits.  

Finally, why should people attend CPHI NA?   

It’s a “one stop shop” for professional and business development!